دورية أكاديمية
أعرض في EDS

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.

التفاصيل البيبلوغرافية
العنوان: Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
المؤلفون: Jones JR; The Institute of Cancer Research, London, UK. Johnjones7@nhs.net.; Brighton and Sussex Medical School, Brighton, UK. Johnjones7@nhs.net.; Kings College Hospital NHS Foundation Trust, London, UK. Johnjones7@nhs.net., Barber A; The Institute of Cancer Research, London, UK., Le Bihan YV; The Institute of Cancer Research, London, UK., Weinhold N; Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany., Ashby C; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Arkansas, USA., Walker BA; Indiana University School of Medicine, Indiana, USA., Wardell CP; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Arkansas, USA., Wang H; The Institute of Cancer Research, London, UK., Kaiser MF; The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK., Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Chopra R; The Institute of Cancer Research, London, UK.; Apple Tree Partners, London, UK., Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, USA., Pawlyn C; The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.; The Royal Marsden Hospital, London, UK. charlotte.pawlyn@icr.ac.uk.
المصدر: Leukemia [Leukemia] 2021 Oct; Vol. 35 (10), pp. 3017-3020. Date of Electronic Publication: 2021 Aug 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
أسماء مطبوعة: Publication: 2000- : London : Nature Publishing Group, Specialist Journals
Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987-
مواضيع طبية MeSH: Drug Resistance, Neoplasm* , Mutation*, Adaptor Proteins, Signal Transducing/*genetics , Biomarkers, Tumor/*genetics , Immunomodulating Agents/*therapeutic use , Multiple Myeloma/*pathology , Ubiquitin-Protein Ligases/*genetics, Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics
References: Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28:1129–31. (PMID: 10.1038/leu.2013.315)
Gooding S, Ansari-Pour N, Towfic F, Ortiz Estévez M, Chamberlain PP, Tsai KT, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137:232–7. (PMID: 10.1182/blood.2020007081)
Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018;7:e38430.
Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, et al. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2018;33:171–180.
Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity. Blood. 2018;132:1293–303. (PMID: 10.1182/blood-2018-01-821769)
Tateno S, Iida M, Fujii S, Suwa T, Katayama M, Tokuyama H, et al. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci Rep. 2020;10:4012. (PMID: 10.1038/s41598-020-61027-w)
Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science. 2013;343:305–9.
Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–5. (PMID: 10.1126/science.1244851)
Sievers QL, Petzold G, Bunker RD, Renneville A, Slabicki M, Liddicoat BJ, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018;362:eaat0572.
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9:19. (PMID: 10.1038/s41408-019-0173-0)
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–35. (PMID: 10.1038/leu.2012.119)
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73. (PMID: 10.1016/S1470-2045(18)30687-9)
Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019;104:1440–50. (PMID: 10.3324/haematol.2018.202200)
Akuffo AA, Alontaga AY, Metcalf R, Beatty MS, Becker A, McDaniel JM, et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J Biol Chem. 2018;293:6187–6200. (PMID: 10.1074/jbc.M117.816868)
Sheereen A, Alaamery M, Bawazeer S, Al Yafee Y, Massadeh S, Eyaid W. A missense mutation in the. J Med Genet. 2017;54:236–40. (PMID: 10.1136/jmedgenet-2016-104117)
معلومات مُعتمدة: 29957 United Kingdom CRUK_ Cancer Research UK
المشرفين على المادة: 0 (Adaptor Proteins, Signal Transducing)
0 (Biomarkers, Tumor)
0 (CRBN protein, human)
0 (Immunomodulating Agents)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
تواريخ الأحداث: Date Created: 20210810 Date Completed: 20211231 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC8478640
DOI: 10.1038/s41375-021-01373-4
PMID: 34373585
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5551
DOI:10.1038/s41375-021-01373-4